A methodological review of US budget-impact models for new drugs
J Mauskopf, S Earnshaw - Pharmacoeconomics, 2016 - Springer
A budget-impact analysis is required by many jurisdictions when adding a new drug to the
formulary. However, previous reviews have indicated that adherence to methodological …
formulary. However, previous reviews have indicated that adherence to methodological …
A systematic review of the budget impact analyses for antitumor drugs of lung cancer
L Han, X Zhang, WQ Fu, CY Sun, XM Zhao… - Cost Effectiveness and …, 2020 - Springer
Abstract Background Budget impact analyses (BIAs) are used for reimbursement decisions
and drug access medical insurance, as a supplement to cost-effectiveness analyses (CEAs) …
and drug access medical insurance, as a supplement to cost-effectiveness analyses (CEAs) …
[HTML][HTML] Next-generation sequencing in NSCLC and melanoma patients: a cost and budget impact analysis
Next-generation sequencing (NGS) has reached the molecular diagnostic laboratories.
Although the NGS technology aims to improve the effectiveness of therapies by selecting the …
Although the NGS technology aims to improve the effectiveness of therapies by selecting the …
Evaluating expected costs and benefits of granting access to new treatments on the basis of progression-free survival in non–small-cell lung cancer
Importance Surrogate end points may be used as proxy for more robust clinical end points.
One prominent example is the use of progression-free survival (PFS) as a surrogate for …
One prominent example is the use of progression-free survival (PFS) as a surrogate for …
Budget impact of dabrafenib and trametinib in combination as adjuvant treatment of BRAF V600E/K mutation-positive melanoma from a US commercial payer …
D Stellato, ME Gerbasi, B Ndife, SR Ghate… - Journal of Managed …, 2019 - jmcp.org
BACKGROUND: Before the approval of dabrafenib and trametinib in combination, there
were no approved therapies in the adjuvant setting that target the RAS/RAF/MEK/ERK …
were no approved therapies in the adjuvant setting that target the RAS/RAF/MEK/ERK …
Budget impact analysis of afatinib for first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions …
J Graham, S Earnshaw, K Burslem, J Lim - Journal of Managed Care & …, 2018 - jmcp.org
BACKGROUND: Afatinib is 1 of 3 tyrosine kinase inhibitors approved in the United States for
the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose …
the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose …
The budget impact of introducing mobocertinib for the postplatinum treatment of advanced non–small cell lung cancer harboring epidermal growth factor receptor exon …
L Hernandez, M Young - Journal of Managed Care & Specialty Pharmacy, 2023 - jmcp.org
BACKGROUND: Lung cancer is a leading cause of cancer morbidity and death in the United
States. Non–small cell lung cancer (NSCLC) accounts for 85% of lung cancer cases, and …
States. Non–small cell lung cancer (NSCLC) accounts for 85% of lung cancer cases, and …
Do current approaches to assessing therapy related adverse events align with the needs of long-term cancer patients and survivors?
SD Pettit, R Kirch - Cardio-oncology, 2018 - Springer
The increasing efficacy of cancer therapeutics means that the timespan of cancer therapy
administration is undergoing a transition to increasingly long-term settings. Unfortunately …
administration is undergoing a transition to increasingly long-term settings. Unfortunately …
中美两国医保预算影响分析研究文献的质量评估
柳鹏程， 顾佳慧， 白铭钰， 董雅琦， 林佳儿… - 中国 …, 2023 - journal.china-pharmacy.com
目的: 为我国医保预算影响分析(BIA) 研究的开展提供经验借鉴. 方法: 在PubMed, ProQuest,
中国知网, 万方和中国生物医学文献服务系统等数据库中检索建库至今的中美两国关于医保BIA …
中国知网, 万方和中国生物医学文献服务系统等数据库中检索建库至今的中美两国关于医保BIA …
Economic impact of tissue testing and treatments of metastatic NSCLC in the era of personalized medicine
DM Graham, NB Leighl - Frontiers in oncology, 2014 - frontiersin.org
A paradigm-shift in the management of non-small cell lung cancer (NSCLC) has resulted in
many new therapies becoming available for patients with advanced disease. Stratification of …
many new therapies becoming available for patients with advanced disease. Stratification of …